To identify new potential targets in oncology, functional approaches were developed using tumor cells as immunogens to select monoclonal antibodies targeting membrane receptors involved in cell proliferation. For that purpose cancer cells were injected into mice and resulting hybridomas were screened for their ability to inhibit cell proliferation in vitro. Based on this functional approach coupled to proteomic analysis, a monoclonal antibody specifically recognizing the human junctional adhesion molecule-A (JAM-A) was defined. Interestingly, compared to both normal and tumor tissues, we observed that JAM-A was mainly overexpressed on breast, lung and kidney tumor tissues. In vivo experiments demonstrated that injections of anti-JAM-A antibody resulted in a significant tumor growth inhibition of xenograft human tumors. Treatment with monoclonal antibody induced a decrease of the Ki67 expression and downregulated JAM-A levels. All together, our results show for the first time that JAM-A can interfere with tumor proliferation and suggest that JAM-A is a potential novel target in oncology. The results also demonstrate that a functional approach coupled to a robust proteomic analysis can be successful to identify new antibody target molecules that lead to promising new antibody-based therapies against cancers.Targeted therapies have revolutionized the treatment of cancers. However, there is a need for innovative targets susceptible to bring new medical treatments. Discovering novel cancer targets, and molecules to interfere with, is a major challenge in oncology research. Among new emerging targets, molecules implicated in cell adhesion, migration and polarity provide promising opportunities to combat tumor proliferation, invasion and metastasis. This is the case of tetraspanins for examples, 1 such as CD151 2 or CD9 3 known to exert prominent roles in cell migration and invasion. Furthermore, their interaction with distinct tyrosine kinase receptors (TKR) accounts for their capacity to modulate cell proliferation. 4 Similarly, integrins and some G protein-coupled receptors can crosstalk with TKR to modulate their activities. 5 Recently, molecules involved in cellular architecture (tight or adherent) junctions have been described as playing a role in the control of cell migration and/or proliferation. 6 The modulation of TKR can also affect cell adhesion molecules such as claudins. 7 In addition, these emerging targets can exert a direct effect by themselves on either tumor cell migration 8 or tumor growth regulation. 9 With the objective to identify new targets in oncology, we initiated a function-based approach to identify new antitumor monoclonal antibodies (Mabs). This innovative approach is based on generation and selection of Mabs that are primarily screened for their capacity to trigger cellular functions, including tumor cell proliferation or tumor apoptosis. By combining these two complementary experimental modalities, we were able to identify a set of tumor-active Mabs and subsequently, for the most potent...
Klebsiella pneumoniae OmpA, the 40-kDa major protein of the outer membrane, was cloned and expressed in Escherichia coli. The recombinant protein was produced intracellularly in E. coli as inclusion bodies. Fusion of a short peptide to the N-terminus of native P40 facilitated high-level expression of the recombinant protein. Purified recombinant P40 was analyzed to verify purity and structural integrity. The molecular mass of purified recombinant P40 determined by electrospray mass spectrometry was 37 061 Da, in agreement with the theoretical mass deduced from the DNA sequence. Specific proliferation of recombinant-P40-primed murine lymph node cells in response to recombinant P40 stimulation in vitro indicated the presence of a T-cell epitope on recombinant P40. The induction of high serum antibody titers to a synthetic peptide derived from the attachment protein G of the respiratory syncytial virus when chemically coupled to recombinant P40 indicated that the protein had potent carrier properties. OmpA [20, 21] have been demonstrated to mediate expression of gram-negative bacteria, present at about 10 5 copies/cell. It is believed to occur in a monomeric form in its native state. A of peptides on the surface of live enterobacterial vectors. OmpC, the outer-membrane protein complex of Neisseria meningitidis, typical feature of OmpA is that it can be modified by heat: the mobility of Escherichia coli OmpA on SDS/PAGE decreases has been shown to be effective in humans as a conjugate vaccine with Haemophilus influenzae, pneumococcal and meningococcal when it is heated in the presence of SDS [1]. OmpA is highly conserved among gram-negative bacteria and is thought to con-capsular polysaccharides [22Ϫ25]. Other clinically useful carrier proteins have been derived from bacteria: diphteria and tetanus sist of two domains. The N terminus, including amino acid residues 1Ϫ170, forms a membrane-spanning domain and crosses toxoids are both successfully used in conjugated H. influenzae vaccines to transform the capsular polysaccharide, which is a Tthe outer membrane eight times in antiparallel β-strands, leading to a typical amphiphilic β-barrel [2Ϫ4]. The C-terminal moiety independent antigen, into a T-dependent antigen [26].
KeywordsIn this paper we describe the expression and production in of the protein is thought to be periplasmic [5]. The protein seems to be multifunctional. In addition to non-physiological functions, E. coli and purification of Klebsiella pneumoniae OmpA [27].Using various analytical criteria, the purity and structural integsuch as serving as a receptor for phages and colicins [6], it serves as a mediator in F-factor-dependent conjugation [7]. It is rity of the protein were evaluated. We demonstrate the presence of at least one T-cell epitope on the molecule and its potential also required for the structural integrity of the outer membrane and the generation of normal cell shape [8]. The capacity to use as a carrier protein for conjugated peptides. The immunological carrier properties of the recombin...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.